MRT-2359 is under clinical development by Monte Rosa Therapeutics and currently in Phase II for Neuroendocrine Cancer. According to GlobalData, Phase II drugs for Neuroendocrine Cancer have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRT-2359’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRT-2359 is under development for the treatment of solid tumors including small-cell lung cancer, non-small cell lung cancer, diffuse large B-cell lymphoma, triple-negative breast cancer (TNBC), multiple myeloma (Kahler disease), neuroendocrine cancer and ovarian cancer. The drug candidate is a molecular glue degrader selectively targeting GSPT1. It is administered orally and is being developed based on Quantitative and Engineered Elimination of Neosubstrates (QuEEN) platform.
Monte Rosa Therapeutics overview
Monte Rosa Therapeutics is a biotechnology company developing small molecules to degrade disease-related proteins. The company is headquartered in Boston, Massachusetts, the US.
For a complete picture of MRT-2359’s drug-specific PTSR and LoA scores, buy the report here.